ClinicalTrials.gg
CompletedNCT04775732Updated Aug 5, 2021

Ultra-proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease

A Phase 4 interventional study of infliximab therapeutic drug monitoring in Crohn Disease and Ulcerative Colitis, sponsored by Imelda GI Clinical Research Center. Completed at 2 sites in Belgium. Per ClinicalTrials.gov, last updated 2021-08-05.

Sponsored by Imelda GI Clinical Research Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Jun 2018, registered Feb 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
187
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Crohn Disease with a site in Belgium — 41 open to participants now, 56 under way, 29 of them phase 3. Crohn Disease · Belgium.

Enrollment
94th of 175
187 · median 211
Started
2018
with 14 others
Phase 4
9 of 194
4 open now
Registered
135th of 194
by date

Among the 194 studies in Crohn Disease with a site in Belgium, this one is the 94th largest by enrollment of the 175 interventional ones that give a count, is one of 15 that started in 2018, is one of 9 in phase 4, and was the 135th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

41 of the 194 studies in Crohn Disease with a site in Belgium are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Crohn Disease with a site in Belgium, or all of them as a file.
02

Study summary

This is a comparative pragmatic trial in patients with UC and CD on maintenance treatment with IFX. All IBD patients from cohort A with maintenance IFX treatment at a referral IBD clinic are prospectively included between June and August 2018. An ultra-proactive IFX TDM algorithm is applied as follows. All patients have an ELISA TL measurement at baseline, of which the result determined the follow-up pathway: (A) TL between 3-7μg/mL: continuation at same dose and interval; (B) TL >7μg/mL: interval prolongation allowed; (C) TL \<3μg/mL: interval shortening with minimum 2 weeks, with the next IFX TL measured using a POCT. (i) If the POCT showed an IFX TL \<3μg/mL, dose was optimized ad hoc using a linear dosing formula (Dosen = (TL target * Dose n-1) / TL measured), followed by a new POCT test at next visit with the same interval. (ii) If the POCT showed an IFX TL ≥3µg/mL, no additional dose was given and routine TL testing with ELISA was retaken at next visit. At every visit this algorithm was reapplied to all patients.

The patients from cohort A will be compared with the patients from cohort B. The patients in cohort B receive maintenance IFX treatment at a referral IBD clinic during the same period. Dose adjustment are done based on standard of care reactive TDM of IFX and clinical symptoms. Data will be collected retrospectively to avoid treatment optimization bias.

03

Conditions studied

  • Crohn Disease
  • Ulcerative Colitis

Keywords

  • therapeutic drug monitoring
  • inflammatory bowel disease
  • point of care testing
  • infliximab
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • all adult IBD patients treated for at least 14 weeks with infliximab were included

Exclusion criteria

Exclusion Criteria:

  • induction treatment with infliximab (\<14 weeks)
  • treatment with other biological for IBD
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    ultra proactive arm

    Biological: infliximab therapeutic drug monitoring

  • Active comparator
    reactive arm

    Biological: infliximab therapeutic drug monitoring

Interventions

  • Biologicalinfliximab therapeutic drug monitoring

    dose optimization of infliximab based on a predefined dosing algorithm

06

What researchers measure

Primary outcomes

  1. number of patients with infliximab failure

    number of patients with infliximab failure after one year (infliximab failure = infliximab discontinuation, IBD related surgery, IBD related hospitalization, add-on IBD treatment, and allergic reaction to infliximab)

    Time frame: one year

Secondary outcomes

  1. number of TL measurements per patient per year

    Time frame: one year

  2. percentage of interval changes (shortening, prolongation, bidirectional)

    Time frame: one year

  3. number of patients with infliximab discontinuation

    number of patients with discontinuation of infliximab

    Time frame: one year

  4. percentage of patients with sustained clinical remission

    number of patients with physician global assessment \<1 and all visits

    Time frame: one year

  5. number of patients with mucosal remission

    number of patients with mucosal remission after one year. (Mucosal remission = simple endoscopic score for CD \<3, Rutgeertscore \<i2 for, Mayo endoscopic subscore \<1 and faecal calprotectin \<250 µg/ml. Endoscopy and/or faecal calprotectin between 6 and 12 months after inclusion. If endoscopy and faecal calprotectin at the same moment, then endoscopy was dominant)

    Time frame: one year

07

Study locations

2 sites
  • Imelda GI clinical research center
    Bonheiden, 2820, Belgium
  • AZ Sint Lucas
    Gent, 9000, Belgium
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Aug 2019, 14 months.

Of 54 non-industry phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 71. This study's 14 months is below that.

Counting every sponsor, half of 70 studies reached it within 56 months; a quarter within 35 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2021
First posted
Mar 1, 2021
StartActual
Jun 1, 2018
Primary completionActual
Aug 31, 2019
CompletionActual
Sep 30, 2019
Last update
Aug 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04775732
Lead sponsor
Imelda GI Clinical Research Center
Responsible party
Peter Bossuyt (MD, Imelda GI Clinical Research Center) — Principal investigator
First posted
Mar 1, 2021
Start date
Jun 1, 2018
Primary completion
Aug 31, 2019
Completion
Sep 30, 2019
Last update
Aug 5, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion